• Explore /
  • Poster
  • / A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Abstract Poster

Authors

null

Koral Shah

Washington University School of Medicine, Saint Louis, MO

Koral Shah , Aravinda Ganapathy , Ariel Borkowski , Nakul Shah , Dhruv Bansal , Rachel Beck , Eric Marshall Knoche , Joel Picus , Melissa Andrea Reimers , Bruce J. Roth , James L. Gulley , Robert Schreiber , Russell Kent Pachynski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Hormone-Sensitive

Clinical Trial Registration Number

NCT03532217

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5068)

DOI

10.1200/JCO.2022.40.16_suppl.5068

Abstract #

5068

Poster Bd #

251

Abstract Disclosures

Similar Posters

First Author: Sofie Kirial Mørk

First Author: Sally Leong

First Author: Shahneen Sandhu

First Author: Padmanee Sharma